| 2.56 -0.2 (-7.25%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.03 |
1-year : | 4.73 |
| Resists | First : | 3.45 |
Second : | 4.05 |
| Pivot price | 3.23 |
|||
| Supports | First : | 2.48 |
Second : | 2.06 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 3.34 |
| MA(100) : | 4.21 |
MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 10.7 |
| RSI | RSI(14): 33.1 |
|||
| 52-week | High : | 20.7 | Low : | 2.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLRB ] has closed above bottom band by 18.7%. Bollinger Bands are 68.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.76 - 2.77 | 2.77 - 2.78 |
| Low: | 2.45 - 2.47 | 2.47 - 2.48 |
| Close: | 2.54 - 2.56 | 2.56 - 2.58 |
Tue, 16 Dec 2025
Cellectar Biosciences Announces Multi-Year Supply Agreement with Ionetix for Alpha-Emitting Radioisotopes - Quiver Quantitative
Thu, 13 Nov 2025
Cellectar (NASDAQ: CLRB) starts Phase 1b study of CLR 125 in triple-negative breast cancer - Stock Titan
Thu, 13 Nov 2025
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Thu, 06 Nov 2025
Cellectar Biosciences (NASDAQ: CLRB) sets Nov. 13 results call for 8:30 a.m. ET - Stock Titan
Tue, 07 Oct 2025
$5.8M Raised: Cellectar Biosciences Secures Funding via Warrant Exercises to Advance CLR 121125 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 7 (%) |
| Shares Short | 154 (K) |
| Shares Short P.Month | 267 (K) |
| EPS | -8.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.4 % |
| Return on Equity (ttm) | -145.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|